Subtopic Deep Dive
Genomic Profiling for Lung Cancer Therapy
Research Guide
What is Genomic Profiling for Lung Cancer Therapy?
Genomic profiling for lung cancer therapy uses next-generation sequencing panels to identify targetable mutations like ROS1, RET, and NTRK beyond EGFR/ALK in lung tumors for personalized treatment selection.
This approach sequences tumor DNA to detect actionable alterations and tumor mutational burden (TMB) for immunotherapy decisions. Studies like the Cancer Genome Atlas Pan-Cancer analysis (Weinstein et al., 2013, 8983 citations) characterized lung cancer genomes comprehensively. Over 10 key papers from 2011-2019 detail profiling in adenocarcinoma and squamous cell lung cancers.
Why It Matters
Genomic profiling guides therapy in advanced NSCLC by matching patients to targeted drugs or immunotherapies based on mutations and TMB (Goodman et al., 2017). It improves survival in metastatic nonsquamous NSCLC with atezolizumab regardless of PD-L1 or EGFR/ALK status (Socinski et al., 2018). Comprehensive profiling reveals co-occurring drivers in squamous cell lung cancers (Getz et al., 2012), enabling resistance prediction (Vasan et al., 2019).
Key Research Challenges
Heterogeneous Tumor Mutations
Lung tumors show diverse co-occurring alterations complicating single-target therapies (Getz et al., 2012). Profiling must capture intratumor heterogeneity for accurate TMB assessment (Goodman et al., 2017). Validation across adenocarcinoma and squamous subtypes remains inconsistent (Travis et al., 2011).
TMB for Immunotherapy Prediction
High TMB predicts PD-1/PD-L1 response in NSCLC but thresholds vary by cohort (Goodman et al., 2017). Co-treatments like nivolumab plus ipilimumab challenge TMB independence (Hellmann et al., 2019). Standardization across pan-cancer datasets is needed (Weinstein et al., 2013).
Drug Resistance Mechanisms
Acquired resistance post-profiling limits targeted therapy duration (Vasan et al., 2019). Profiling must integrate resistance pathways from prior treatments (Longley and Johnston, 2005). ESMO guidelines highlight need for repeat profiling in metastatic NSCLC (Novello et al., 2016).
Essential Papers
The Cancer Genome Atlas Pan-Cancer analysis project
John N. Weinstein, Jun Li, Gordon B. Mills et al. · 2013 · Nature Genetics · 9.0K citations
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D. Travis, Élisabeth Brambilla, Masayuki Noguchi et al. · 2011 · Journal of Thoracic Oncology · 4.8K citations
Comprehensive genomic characterization of squamous cell lung cancers
Gad Getz, Stephen E. Schumacher, Petar Stojanov et al. · 2012 · Nature · 3.9K citations
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · 2018 · New England Journal of Medicine · 3.6K citations
The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NSCLC, regardless of P...
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine et al. · 2016 · The Lancet · 3.3K citations
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
Matthew D. Hellmann, Luis Paz‐Ares, Reyes Bernabé et al. · 2019 · New England Journal of Medicine · 2.7K citations
First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new...
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Silvia Novello, Fabrice Barlési, Raffaele Califano et al. · 2016 · Annals of Oncology · 2.6K citations
Reading Guide
Foundational Papers
Start with TCGA Pan-Cancer (Weinstein et al., 2013) for broad genomic landscapes, then adenocarcinoma classification (Travis et al., 2011) and squamous profiling (Getz et al., 2012) to understand lung-specific mutations.
Recent Advances
Study TMB as immunotherapy biomarker (Goodman et al., 2017), atezolizumab trials (Socinski et al., 2018), and nivolumab combos (Hellmann et al., 2019) for clinical translation.
Core Methods
Next-generation sequencing for mutation panels, TMB calculation via exome sequencing, and pan-cancer integration as in Weinstein et al. (2013); survival analysis tools from Győrffy et al. (2013).
How PapersFlow Helps You Research Genomic Profiling for Lung Cancer Therapy
Discover & Search
Research Agent uses searchPapers and exaSearch to find profiling papers like 'Tumor Mutational Burden as an Independent Predictor' (Goodman et al., 2017), then citationGraph reveals connections to TCGA Pan-Cancer (Weinstein et al., 2013) and findSimilarPapers uncovers NSCLC-specific TMB studies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract TMB thresholds from Goodman et al. (2017), verifies claims with CoVe against Socinski et al. (2018), and runs PythonAnalysis for survival correlations using NumPy/pandas on extracted data, graded by GRADE for evidence strength in immunotherapy contexts.
Synthesize & Write
Synthesis Agent detects gaps in ROS1/RET coverage across papers, flags TMB contradictions between lung subtypes; Writing Agent uses latexEditText, latexSyncCitations for TCGA/Goodman refs, and latexCompile to generate profiling workflow diagrams via exportMermaid.
Use Cases
"Compute TMB-response correlation from NSCLC immunotherapy trials"
Research Agent → searchPapers(Goodman 2017, Hellmann 2019) → Analysis Agent → readPaperContent → runPythonAnalysis(pandas correlation on extracted survival data) → statistical p-value and plot output.
"Draft LaTeX review on genomic profiling in squamous lung cancer"
Synthesis Agent → gap detection(Getz 2012 vs Travis 2011) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(TCGA refs) → latexCompile → compiled PDF with mutation diagram.
"Find code for lung cancer genomic analysis pipelines"
Research Agent → searchPapers(Weinstein 2013) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → repo with NGS processing scripts and usage guide.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'lung cancer TMB profiling', chains citationGraph to TCGA (Weinstein et al., 2013), and outputs structured report with GRADE-scored evidence. DeepScan applies 7-step CoVe to verify TMB claims from Goodman et al. (2017) against Hellmann et al. (2019) trials. Theorizer generates hypotheses on RET/NTRK co-mutations from pan-cancer profiles.
Frequently Asked Questions
What is genomic profiling in lung cancer therapy?
It involves NGS panels to detect mutations like ROS1/RET/NTRK and TMB for therapy selection beyond EGFR/ALK (Goodman et al., 2017).
What methods validate TMB for immunotherapy?
Whole-exome sequencing computes TMB as mutations per megabase, predicting PD-1 response independently in NSCLC (Goodman et al., 2017; Socinski et al., 2018).
What are key papers on lung cancer genomic profiling?
TCGA Pan-Cancer (Weinstein et al., 2013, 8983 citations), squamous profiling (Getz et al., 2012, 3932 citations), and TMB predictor (Goodman et al., 2017, 2324 citations).
What open problems exist in genomic profiling?
Standardizing TMB thresholds across subtypes, integrating resistance mechanisms (Vasan et al., 2019), and repeat profiling for metastatic progression (Novello et al., 2016).
Research Lung Cancer Treatments and Mutations with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Genomic Profiling for Lung Cancer Therapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers